Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time). Keytruda is used in adults and some children with certain advanced forms of the following types of ...

Although Keytruda/Inlyta had a higher rate of adverse ... The novel treatment options involves patients attending bi-weekly for an IV infusion, allowing healthcare professionals to monitor ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Patients in the study will receive a 1 mg dose of V940 via intramuscular (IM) injection or a matched placebo once every three weeks for up to nine doses, along with an infusion of Keytruda once ...

Though she’s undergone chemotherapy and radiation, she still needs an infusion of the costly immunotherapy medication Keytruda every six weeks to give her the best chance of survival.

In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar potential: It holds a first-mover advantage in one of the largest cancer indications of non-small cell ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

Patients were randomized (1:1) to receive either: Keytruda (200 mg IV) Q3W for five cycles concurrent with cisplatin (40 mg/m 2 IV) weekly for five cycles (an optional sixth infusion could be ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...